2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

3697 Tafasitamab is active in relapsed central nervous system lymphomas:  results of a Phase I trial with lenalidomide, CSF pk evaluation, and monotherapy in an intracranial PDX model

Michael Paul Randall, MD, Andreas Rauschecker, M.D., Ph.D.2, Lingjing Chen, Ph.D.3, Ming Lu, B.S.4, Damien Molaro5, Isabelle Molina6, Alexis Voegele7, Haifaa Abdulhaq, Clinical Professor8, Rosalynn Ofel Sanchez Ruiz, BSN9, Jordan Roselli10, Huimin Geng, PhD11, John Gonzales, MD12, Armin Afshar, MD13, James Louis Rubenstein, M.D., Ph..D.14
1 UCSF, San Francisco, California, United States
2 Helen Diller Family Comprehensive Cancer Center, San Francisco, United States, UCSF, San Francisco, United States
3 UCSF, San Francisco, California, United States
4 UCSF, San Francisco, California, United States
5 Eurofins, Vergeze, France
6 Eurofins, Vergeze, France
7 Eurofins, Vergeze, France
8 UCSF, San Francisco, California, United States
9 UCSF, San Francisco, California, United States
10 UCSF, San Francisco, California, United States
11 Helen Diller Family Comprehensive Cancer Center, San Francisco, United States, UCSF, San Francisco, United States
12 UCSF, San Francisco, California, United States
13 Helen Diller Family Comprehensive Cancer Center, San Francisco, United States, UCSF, San Francisco, California, United States
14 Helen Diller Family Comprehensive Cancer Center, San Francisco, United States, UCSF, San Francisco, California, United States

Introduction

Development of effective, chemotherapy-free, biological therapies to treat primary and secondary CNS lymphoma (CNSL) is a significant priority.   We are evaluating tafasitamab, a humanized anti-CD19 monoclonal antibody, engineered for enhanced ADCC, as a novel agent for relapsed/refractory CNSL.  Our hypothesis is that tafasitamab may partially disrupt blood-brain barrier integrity by perturbation of CD19-positive vascular pericytes and  mediate efficacy without cytokine release syndrome.  Our rationale is supported by the Phase II L-MIND study demonstrating synergistic efficacy of tafasitamab plus lenalidomide in refractory aggressive non-Hodgkin lymphoma. with a favorable toxicity profile compared to CAR-T.  Notably, the L-MIND trial excluded CNSL and patients previously treated with IMiDs.  In addition, we reported brain parenchymal regressions in response to tafasitamab plus lenalidomide in 2 patients with refractory CNSL resistant to methotrexate, lenalidomide, pomalidomide and rituximab; one of these responses has been durable for >5 years (PMID: 36691708).

 

Methods

We performed a single-arm, open-label Phase I study (NCT05351593) to determine safety, CNS pharmacokinetics and preliminary efficacy of tafasitamab plus lenalidomide in patients with relapsed primary and secondary CNSL. The protocol evaluates tafasitamab (12 mg/kg) in combination with 3 dose levels of lenalidomide, using 3 + 3 dose escalation rules, comparing 10mg, 15mg and 20 mg/day, to determine a recommended phase 2 dose (RP2D).  Pharmacokinetic analyses are performed via quantitative measurement of tafasitamab in plasma and CSF, collected via ventricular access device or lumbar puncture.   Preclinical studies of tafasitamab are conducted using an intracranial model of CNSL in RAG-/- mice with stereotactic injection of patient-derived tumor cells derived from aMYD88/CD79B mutant, relapsed/refractory primary CNS lymphoma.

 

Results

Fifteen patients (13 PCNSL, 2 SCNSL) have been treated; median age 69 (range 61-76 years). Racial and ethnic distribution of study subjects included 10 Whites, four Asians and one Hispanic patient.  All had KPS>70.  Median prior lines of therapy was 3 with 6 patients having progressed on an IMiD.  Tumors from 9 of 11 subjects with baseline lymphoma mutational data contained high-risk genomic aberrations. (PMID: 39536287).  Three subjects received lenalidomide at the 10 mg/day dose level and six patients respectively were treated at 15 mg/day and 20 mg/day dose levels.  The combination has been well tolerated with grade 3 toxicities of UTI and pneumonia (each one patient) detected at the 15 mg and 20 mg/day cohorts.  There has been no neurotoxicity.  Thus far, 12 patients exhibited responses in brain parenchyma, leptomeningeal and intraocular compartments: 5 CR, 8PR.  Median time to best response was 24 days. With median follow-up of 14.6 months, estimated median PFS is 6.0 months.   Five patients remain on study with longest response exceeding 15 months.  Ten patients are alive at data cut-off.   There was no significant difference in PFS or OS between patients with and without prior IMiD exposure.

Preliminary CSF PK analysis demonstrated tafasitamab penetration into CSF in 10 of 12 post-dose specimens analyzed thus far, with time-dependent accumulations in ventricular CSF, with highest concentrations reproducibly detected at cycle 2 and 3.  In one patient, CSF concentrations of tafasitamab were > 5 mg/ml, exceeding reported CSF concentrations of rituximab after IV administration.  (PMID: 12393404).

Finally, as proof of concept, tafasitamab monotherapy yielded 30% survival prolongation (P<0.0006) in a patient-derived intracranial xenograft model of ibrutinib-refractory relapsed PCNSL, compared to control IgG1 (each 12 mg/kg).

 

Conclusions

Tafasitamab plus lenalidomide was well-tolerated in a heavily-treated, older, relapsed CNSL patient population with encouraging efficacy.  Evidence for the clinical benefit of tafasitamab was obtained on trial and substantiated by results using a relevant preclinical model of CNSL.  Determination of the RP2D of lenalidomide in combination with tafasitamab is pending.  Ongoing CSF analysis provides evidence, for the first time to our knowledge, for reproducible time-dependent accumulation of tafasitamab in ventricular CSF, and pharmacokinetic modeling is planned.  These results support further studies of tafasitamab in primary and secondary CNSL.

Supported by Blood Cancer United

 

 

James Louis Rubenstein, M.D., Ph..D.: No relevant conflicts of interest to declare.